Justice Department to Charge 450 Defendants in $6.5B Healthcare Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
The Justice Department is expected to charge around 450 defendants for alleged healthcare fraud totaling over $6.5B, The Wall Street Journal's Sabrina Siddiqui and Christopher Weaver reports. The operation spans 57 federal-court districts and 41 states, including 90 medical professionals and over 100 Medicaid fraud defendants, according to the report, which adds that the Justice Department will unveil new data-sharing agreements with the FTC, Homeland Security, and CMS to expand fraud detection. Publicly traded companies in the space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 281.980
Low
300.00
Averages
335.63
High
378.00
Current: 281.980
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cigna Group to Release Q2 2026 Financial Results
- Earnings Release Schedule: The Cigna Group will release its Q2 2026 financial results on July 30, 2026, with results expected by 6:30 a.m. ET, followed by a management conference call at 8:30 a.m. to discuss financial performance.
- Conference Call Details: Participants are advised to dial in by 8:15 a.m. ET on July 30, with domestic call-in numbers at (888) 566-1889 and international at (773) 799-3989, using passcode 07302026.
- Replay Information: A replay of the conference call will be available from 12:30 p.m. ET on July 30 until 10:59 p.m. ET on August 13, with domestic replay at (866) 405-7290 and international at (203) 369-0603, ensuring investors can access the information at their convenience.
- Webcast Availability: The conference call will also be available via live internet webcast on Cigna Group's investor relations website, although this feature will be in listen-only mode, allowing a broad range of investors to stay informed with the latest updates.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
UBS Identifies Attractive Defensive Stock Opportunities
- Market Concentration Analysis: According to UBS, the market experienced strong gains in the first half of the year, primarily driven by a handful of megacap tech companies, leading to historically low correlations across stocks, indicating that investors are avoiding lower-risk companies, which has made many defensive stocks attractive in valuation.
- Valuation Gap in Defensive Stocks: Analyst Sean Burns highlighted that the gap between expensive and cheap defensive stocks is near the widest levels seen since 1990, nearly double the long-run average, with low-risk stocks trading at a market-implied yield of 4.4% compared to just 1.4% for high-risk stocks.
- Quality Defensive Stock Screening: UBS screened for defensive stocks with a market cap of at least $5 billion and a negative correlation to the S&P 500 over the past year, finding that these stocks not only exhibit low volatility but are also trading at discounts, all rated as buys by UBS.
- Individual Stock Performance Expectations: For instance, PepsiCo (PEP) is down about 6% year-to-date but is expected to report strong second-quarter earnings, with its North American food business recovering volume growth after price cuts; McDonald's (MCD) also beat first-quarter earnings expectations and is expected to continue gaining market share globally.
See More
Cigna Invests $100M in New Specialty Care Program
- Program Launch: Cigna's health services division, Evernorth, launched a new specialty care program named Fast Forward with a $100M investment aimed at accelerating care delivery and improving patient outcomes, projected to generate approximately $400M in value by 2028.
- Patient Reach: The program will initially roll out across Evernorth's Accredo Specialty Pharmacy, targeting over one million patients suffering from chronic and complex health conditions annually, showcasing its potential in enhancing patient care.
- AI Integration: Fast Forward aims to leverage artificial intelligence across four key areas in the pharmacy value chain, with expectations to improve medication adherence above 80% and reduce clinician documentation time by up to 50%, thereby enhancing overall operational efficiency.
- Strategic Commitment: Matt Perlberg, who leads Evernorth's pharmacy and care delivery operations, emphasized that the program reflects the company's commitment to delivering a faster, seamless experience while ensuring patients receive personalized support and clinical care.
See More
Cigna Launches New Military Service Grant
- New Grant Launch: The Cigna Group Foundation has announced the launch of the $1.5 million 'Courage in Service' grant, aimed at supporting the health and well-being of military and veteran communities, reflecting the company's long-standing commitment to this demographic.
- Annual Funding Program: Each year, $150,000 will be awarded to a nonprofit organization to support programs that strengthen social connections, improve well-being, and increase stability for military families navigating key life transitions.
- CEO Retirement and Legacy: The grant's introduction coincides with David Cordani's retirement as CEO of The Cigna Group, transitioning to executive chair of the board, marking a continuation of his 17-year focus on supporting military communities.
- Application Open and Timeline: Grant applications are now open until July 30, 2026, with funding expected to commence on January 1, 2027, further enhancing support for military and veteran communities.
See More
Cigna Group to Release Q2 2026 Financial Results
- Earnings Release Schedule: The Cigna Group will release its Q2 2026 financial results on July 30, 2026, with results expected by 6:30 a.m. ET, followed by a management conference call at 8:30 a.m. to discuss financial performance.
- Conference Call Details: Participants are advised to dial in by 8:15 a.m. ET on July 30, with domestic call-in numbers at (888) 566-1889 and international at (773) 799-3989, using passcode 07302026.
- Replay Information: A replay of the conference call will be available from 12:30 p.m. ET on July 30 until 10:59 p.m. ET on August 13, with domestic replay at (866) 405-7290 and international at (203) 369-0603, ensuring investors can access the information at their convenience.
- Webcast Availability: The conference call will also be available via live internet webcast on Cigna Group's investor relations website, although this feature will be in listen-only mode, allowing a broad range of investors to stay informed with the latest updates.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
UBS Identifies Attractive Defensive Stock Opportunities
- Market Concentration Analysis: According to UBS, the market experienced strong gains in the first half of the year, primarily driven by a handful of megacap tech companies, leading to historically low correlations across stocks, indicating that investors are avoiding lower-risk companies, which has made many defensive stocks attractive in valuation.
- Valuation Gap in Defensive Stocks: Analyst Sean Burns highlighted that the gap between expensive and cheap defensive stocks is near the widest levels seen since 1990, nearly double the long-run average, with low-risk stocks trading at a market-implied yield of 4.4% compared to just 1.4% for high-risk stocks.
- Quality Defensive Stock Screening: UBS screened for defensive stocks with a market cap of at least $5 billion and a negative correlation to the S&P 500 over the past year, finding that these stocks not only exhibit low volatility but are also trading at discounts, all rated as buys by UBS.
- Individual Stock Performance Expectations: For instance, PepsiCo (PEP) is down about 6% year-to-date but is expected to report strong second-quarter earnings, with its North American food business recovering volume growth after price cuts; McDonald's (MCD) also beat first-quarter earnings expectations and is expected to continue gaining market share globally.
See More
Cigna Invests $100M in New Specialty Care Program
- Program Launch: Cigna's health services division, Evernorth, launched a new specialty care program named Fast Forward with a $100M investment aimed at accelerating care delivery and improving patient outcomes, projected to generate approximately $400M in value by 2028.
- Patient Reach: The program will initially roll out across Evernorth's Accredo Specialty Pharmacy, targeting over one million patients suffering from chronic and complex health conditions annually, showcasing its potential in enhancing patient care.
- AI Integration: Fast Forward aims to leverage artificial intelligence across four key areas in the pharmacy value chain, with expectations to improve medication adherence above 80% and reduce clinician documentation time by up to 50%, thereby enhancing overall operational efficiency.
- Strategic Commitment: Matt Perlberg, who leads Evernorth's pharmacy and care delivery operations, emphasized that the program reflects the company's commitment to delivering a faster, seamless experience while ensuring patients receive personalized support and clinical care.
See More
Cigna Launches New Military Service Grant
- New Grant Launch: The Cigna Group Foundation has announced the launch of the $1.5 million 'Courage in Service' grant, aimed at supporting the health and well-being of military and veteran communities, reflecting the company's long-standing commitment to this demographic.
- Annual Funding Program: Each year, $150,000 will be awarded to a nonprofit organization to support programs that strengthen social connections, improve well-being, and increase stability for military families navigating key life transitions.
- CEO Retirement and Legacy: The grant's introduction coincides with David Cordani's retirement as CEO of The Cigna Group, transitioning to executive chair of the board, marking a continuation of his 17-year focus on supporting military communities.
- Application Open and Timeline: Grant applications are now open until July 30, 2026, with funding expected to commence on January 1, 2027, further enhancing support for military and veteran communities.
See More
